Implantica Announces the Eighth RefluxStop™ Center of Excellence in Italy
Implantica AG (publ.), a pioneering medtech company, has unveiled a significant milestone with the establishment of a new hospital performing the RefluxStop™ procedure in Italy: Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone.
In late March 2024, Prof. Antonio Agrusa, along with Prof. Sebastiano Bonventre and Prof. Giorgio Romano, conducted four RefluxStop™ procedures at the Azienda Ospedaliera Universitaria Policlinico “Paolo Giaccone” in Palermo, Sicily. All four patients have since recovered from surgery and are experiencing relief from the relentless symptoms of chronic GERD without the need for PPI medication.
Prof. Agrusa expressed pride in leading the way to a new standard in the surgical treatment of GERD for patients in Sicily, highlighting the advantages of RefluxStop™ in offering a surgical option that does not encircle the food passageway, thereby making it accessible to a broader range of patients. Prof. Bonventre emphasized the significance of RefluxStop™ in providing relief to patients who have exhausted other treatment options, citing its potential to address the needs of the substantial percentage of patients who do not respond to PPIs. Prof. Romano underscored the lower incidence of side effects associated with RefluxStop™ compared to traditional GERD surgical treatments, affirming its potential to offer a better patient experience.
Maria Grazia Furnari, the Extraordinary Commissioner of the Policlinic Giaccone, emphasized the hospital’s commitment to excellence and innovation in healthcare, citing the implementation of RefluxStop™ therapy as a testament to the institution’s dedication to providing cutting-edge treatment options to patients.
Implantica CEO and founder Dr. Peter Forsell highlighted the widespread prevalence of GERD in Italy and the urgent need for innovative surgical options to address this condition. He expressed pride in supporting the A.O.U. Policlinico Paolo Giaccone and its medical team in bringing RefluxStop™ to their patients, further expanding the reach of this groundbreaking GERD treatment.
With the addition of Policlinico Giaccone, Implantica now boasts more than 25 RefluxStop™ centers across Europe, with dozens more in the evaluation phase, reflecting the growing demand for this advanced GERD treatment.
RefluxStop™ is a revolutionary treatment offering a unique mechanism of action that differentiates it from standard surgical solutions for GERD. Unlike traditional options that involve encircling the food passageway, RefluxStop™ treats the cause of acid reflux without putting pressure on the food passageway, thereby restoring and maintaining the lower esophageal sphincter in its natural position. This innovative approach aims to provide patients with effective relief from GERD symptoms while minimizing side effects commonly associated with traditional surgical treatments.
Implantica is dedicated to advancing innovation in medtech, with a focus on bringing advanced technology into the body. The company’s commitment to research and development underscores its mission to develop transformative solutions that enhance patient outcomes and quality of life.
For further information, please contact:
Nicole Pehrsson, Chief Corporate Affairs Officer
Telephone (CH): +41 (0)79 335 09 49
Email: nicole.pehrsson@implantica.com
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company’s Certified Adviser is FNCA Sweden AB, info@fnca.se
The information was sent for publication, through the agency of the contact person set out above, on May 14, 2024, at 08:00 a.m. (CET).
About Implantica
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energizing platform designed to power remote-controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB).
About RefluxStop™
RefluxStop™ is a new innovative treatment that has the potential to spur a paradigm shift in anti-reflux surgery. It’s unique mechanism of action differentiates it from standard of care and current surgical solutions. Longer established surgical options for GERD involve encircling the food passageway to support the lower esophageal sphincter’s closing mechanism and are commonly associated with side effects such as swallowing difficulties, pain when swallowing and inability to belch and/or vomit.
In contrast, the RefluxStop device treats the cause of acid reflux without encircling and putting pressure on the food passageway. It restores and maintains the lower esophageal sphincter in its original, natural position.
The RefluxStop™ mechanism of action is focused on reconstructing all three components of the anti-reflux barrier, that if compromised could possibly result in acid reflux. It restores and supports the natural anatomical physiology of the body allowing the body to itself solve the problem with acid reflux.
Related posts:
Does Adderall Cause Acid Reflux?
Fusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates
Probiotics Market Surges as Gut Health Takes Center Stage in Global Wellness
Qilu Pharmaceutical Announces Results from Phase II Study for iparomlimab for Advanced Solid Tumors at ESMO Asia, with an ORR of 45.8%
